ReviewJournal of ovarian research2025
RNA sequencing in ovarian cancer research: a comprehensive review.
Review in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
As a highly fatal and heterogeneous disease, ovarian cancer (OC) lacks sufficient treatment choices. Over the past decade, RNA sequencing (RNA-seq) has profoundly changed research methods in molecular biology, enabling comprehensive analysis of transcriptomes, somatic mutations, and tumour heterogeneity. In OC research, the application of RNA-seq technologies has significantly enhanced scientists' understanding of the biological mechanisms underlying the disease, providing deeper insights into the intrinsic mechanisms of key processes such as tumour initiation, metastasis progression, drug resistance formation, and immune evasion. This breakthrough not only expands our understanding of OC but also holds promise for the discovery of novel diagnostic biomarkers, the development of innovative therapies, and the establishment of precise prognostic assessment systems. This review summarizes RNA-seq technologies and their applications in OC research, while also discussing the challenges and opportunities for their broader implementation in cancer studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.